°Q½×°Ï>ªYÄ£¥ÍÂå
¥«³õ­º¨£·sÃÄ ±ÂÅv½Í¤¤
·|­û:hung1201 10149413 µoªí®É¶¡:2020/6/24 ¤U¤È 02:11:23
¥«³õ­º¨£·sÃÄ(¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸) Àø®Ä¤ÀªR p=0.009

6634 ªYÄ£

ªÑ¥»: 3.832»õ

¥D­n·~°È:

¨xŦ¯e¯fªvÀø¤Î¯kµhªvÀø¬ÛÃöÃĪ«¬ã¨s¤Î¶}µo

¸³ºÊ«ùªÑ¤ñ¨Ò: 21.7%(¼W¥[¤¤)

¥~¸ê«ùªÑ¤ñ¨Ò: 0.22%(¼W¥[¤¤)

Ä~Äò©¹¤U¬Ý...!

=============================================================================

²£«~01¡GSNP-610 (ªvÀø¯×ªÕ¨x¯e¯f·sÃÄ)

¾AÀ³¯g: «D°sºë©Ê¯×ªÕ¨xª¢

²£«~Àu¶Õ:

1.¥Ø«e©|µL¼Ð·ÇªvÀøÃĪ«

2.¥«³õ­º¨£·sÃÄ(First-in-class)

3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x

4.µL¦w¥þ©Ê°ÝÃD

¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C

Ävª§¤O:

1.¦h­«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢

2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A­°§C¨x¯×

3.¥i´£¥X¨uÃĥӽСAÀ³¥Î©óªvÀø§³®W«æ©Ê¯×ªÕ¨x

¬ãµo¶¥¬q:

1.¤w³q¹LUSFDA¤ÎTFDA¼f¬d¶i¤JÁ{§É¤G´Á

2.Á{§ÉÀø®Ä¤Î·sªvÀø¾÷ÂàÅçÃÒ

Àø®Ä¤ÀªR¡G

1.²Ä¤@´ÁÁ{§É¸ÕÅç¡Gµ²ªGÅã¥Ü¤HÅé¨Ï¥Î¦w¥þ¡A©Ê½è¨}¦n

2.²Ä¤G´ÁÁ{§É¸ÕÅç¨ä¤¤¤ÀªR¡G17¦ìNASH ¯f¤H (p=0.009)

=============================================================================

²£«~02¡GSNP-630

¾AÀ³¯g:«D°sºë©Ê¯×ªÕ¨xª¢

²£«~Àu¶Õ:

1.¬°Àu¤Æ(Optimized)¤§·s¤Æ¾Ç¹êÅé(NCE)

2.¥«³õ­º¨£·sÃÄ(First-in-class)

3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x

4.§@¬°²Ä¤@¥N²£«~¤W¥««áªº±µÄò¦û¦³¥«³õ¤§²£«~

¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C

Ävª§¤O:

1.¦h­«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢

2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A­°§C¨x¯×

3.Àu¤ÆªºÀø®Ä±j«×¡B§@¥Î®É¶¡

4.µL¦w¥þ©Ê°ÝÃD

¬ãµo¶¥¬q:

1.Á{§É«e

2.¹w©w¥Ó½Ð¬ü°êFDAIND¡B§Ö³t³q¹D(fasttrack)¡C

3.¥Ó½Ð¬ü°ê¬ð¯}©ÊªvÀø(breakthrough therapy)ªº»{©w¡C

Àø®Ä¤ÀªR¡G

1. ¥Ø«e¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.05

=============================================================================

²£«~03¡GSNP-810 (µL¨x¬r©Ê¤îµh·sÃÄ¡B¸Ñ¬r¾¯)

¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃÄ (¸Ñ¼öÂíµh¾¯)

²£«~Àu¶Õ:

1.¦w¥þ¤Æ¦Xª«·s²Õ¦X¡BµL¨x¬r©Ê

2.¸Ñ¨M­¢¤ÁÂåÀø»Ý¨D (Important urgent unmet medical needs)

3.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥i­×§ï©Î§R°£FDA¨x¬rĵ»y¥i¼W¥[¾¯¶q

¥«³õ: ¤AñQÓi×ô¶È¦b¬ü°ê¤@¦~´N¦³40»õ¬ü¤¸ªº¥«³õ

Ävª§¤O:

1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ«

2.¥i§ð¦û¼s¤j¥«³õ¡]NSAID, COX-2 §í¨î¾¯¡BOpioidsÃþ¤îµhÃÄ¥«³õ¡^

3.¥i¬Ù°£¶D³^¶O¡B±Ð¨|°V½m¶O

¬ãµo¶¥¬q:

1.¤w§¹¦¨§C¾¯¶q¡B°ª¾¯¶qÁ{§É¸ÕÅç

2.¤w¥Ó½ÐUSFDA¼Ï&#32445;Á{§É¸ÕÅç¡B±N¥Ó½Ð¬ð¯}©Ê¼f¬d/§Ö³t³q¹D

3.µL¨x¬r©Ê¤AñQÓi×ô¸Ñ¬r¾¯¦¨¤À¡A¤w¥Ó½Ð¬dÅçµn°O¥Î¤§Á{§É¸ÕÅç

=============================================================================

²£«~04¡GSNP-830/ SNP-840

¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃĽƤè(ªvÀø¤¤¡B­««×¯kµh)

²£«~Àu¶Õ:

1.µL¨x¬r©Ê¤AñQÓi×ôªº½Æ¤è

2.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥i­×§ï©Î§R°£FDA¨x¬rĵ»y¡A¥i¼W¥[¾¯¶q

¥«³õ: ¤AñQÓi×ô³B¤èÃĦb¬ü°ê¤@¦~´N¦³27»õ¬ü¤¸ªº¥«³õ

Ävª§¤O:

1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ«½Æ¤è

2.½Æ¤è¤w¥Ñ¬ü°êFDA­n¨D­°¾¯¶q§C©ó325²@§J¡A±N¼vÅTÀø®Ä

3.¦³¨Ï¥Î±M§Q¡A¥i­×§ï©Î§R°£FDA¨x¬rĵ»y

4.¥i¼W¥[¤AñQÓi×ô¾¯¶q

¡]¥Ñ325mg ¦^´_¦Ü500 mg¬Æ¦Ü§ó°ª¡A·|¸û¦³®Ä¡^¥H¼W¥[Àø®Ä¡A©Î´î¤ÖOpioids¾¯¶q¡A­°§C¦¨Å}°Æ§@¥Î

5.¤GªÌ¾Ü¤@±ÂÅv

6.¥i¼W¥[¥«¦û²v

¬ãµo¶¥¬q:

1.SNP-810¨ú±oÃÄÃÒ«á¡A¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê¸ÕÅç

SNP-830 ¤£¬O ·s¦¨¤À ªº·sÃÄ¡A©Ò¥H¤£»Ý­n¶i¦æ²Ä¤@¡A¤G¤Î¤T´ÁÁ{§É´úÅç

µ¥ SNP-810 ®³¨ìÃÄÃÒ«á¡A¥H ·sÀø®Ä½Æ¤è¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê´úÅç ´N¥i¥HÀò±oÃÄÃÒ

=============================================================================

*****************************************************************************

SNP-8 ¨t¦C Àø®Ä¤ÀªR¡G

1. ¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005

1. ¤w¸g§¹¦¨¤§¤HÅé¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005

=============================================================================

*****************************************************************************

¥¼¨Ó¥Ø¼Ð±ÂÅv¥D¤O²£«~¡G

1. ¯×ªÕ¨xÃÄ¡GSNP-610 ©M SNP-630 ¦U¦³ÀuÂI¡A¥Ø¼Ð¬°¥þ²y±ÂÅv

2. ¤îµhÃÄ(OTC): SNP-810, ¥Ø¼Ð¬°¬ü°ê¤Î¥þ²y±ÂÅv

3. ¤îµhÃÄ(³B¤èÃÄ): SNP-830 ¤Î SNP-840, ¦b°Êª«¤W¬Ò¦³¥¿­±ªºµ²ªG¡A¥Ø¼Ð¬°¥þ²y±ÂÅv

=============================================================================

*****************************************************************************

¥Ø«e¤½¥q»P°ê»Ú¤j«¬Ãļt¥¿¦b½Í§Þ³N±ÂÅv©M¦X§@­p¹º

§Ú¬Ý¹L¤½¥q©xºô©M©Ò´£¨Ñªº¸ê®Æ¡Aı±o¤½¥q«Ü¥Î¤ß¦b¸gÀç¡A¦Ó¥B¸ê®Æ¤]«Ü¸Ô²Ó

¹ï¤½¥qµo®i«Ü¦³¦Û«H¡A¥¼¨ÓªÑ»ù­È±o´Á«Ý¡A¦³¾÷·|¬O ¤U¤@­Ó ¦X¤@ ÄƪÑ

-----------------------------------------------------------------------------

¥H¤W¸ê®Æ ³£°Ñ¦Ò ªÑªF·|ij¨Æ¿ý.pdf ©M ¤½¥q©xºô (¦³¿³½ìµÛÅwªï¦A²`¤J¬ã¨s»P°Q½×)

·|­û:dk10140377µoªí®É¶¡:2022/10/20 ¤U¤È 02:38:14²Ä2625½g¦^À³
°ò¥»­±/®ø®§­±°¾¥¿¦V¬Ý«Ý§a¡A¦ý§Þ³N­±´N¬O«Ü®t

¬Ý¬Ý¬O¤£¬O¨«¦X¤@(¥þ³Ó)ªº¸ô¡A·d­Óleo±ÂÅvª÷Åo ©Î

¬O¾ÇÄ_¹sªºµÇÃÄ¡A­n¤@ª½¦Y¡C

===================================

³ø¾É¡G¦bÁ{§É¸ÕÅ礤¡A±µ¨üªvÀøªº±wªÌ¦b²Ä12¶g®ÉªºALT»P°ò½u­È¬Û¤ñ¦³ÅãµÛ­°§C¡A¨S¦³Æ[¹î¨ìÄY­«ªº¤£¨}¨Æ¥ó¡C¦¹¥~¡ASNP-630¦³®Ä¥NÁª«ªí²{¥X§ÜÅÖºû¤Æªº¼ç¤O¡A¥]¬AÅãµÛ­°§CÅÖºû¤Æ¬ÛÃöªº¥Íª«¼Ð°O(§YCCL4©MCCL5)¡C¦¹¥~¡AFibroScan´ú¶q¥çÅã¥Ü¨ä§ïµ½¨xÅÖºû¤Æªº¥\®Ä¡C

·|­û:¦V«e¦æ10140498µoªí®É¶¡:2022/10/20 ¤U¤È 01:17:39²Ä2624½g¦^À³
¨S¦³¡uÄY­«¡v¤£¨}¤ÏÀ³

¤£¥Nªí¨S¦³¤£¨}¤ÏÀ³

·|­û:½²ºû¤¯10143700µoªí®É¶¡:2022/10/20 ¤U¤È 12:10:56²Ä2623½g¦^À³
¦¹¦¸¦h¤F¨S¦³¤£¨}¤ÏÀ³¨Æ¥ó¡m³o¬O³\¦h¨ä¥L¨xÃĸؤ£¹LªºÄæ¡AÂର¨ä¥LÃij~¥u¦n¡n¡F¯à¦bÃľǷ|µoªí¡A¹üÅãÀu¶V©Ê»P¥þ²yÃn¥ú¡AÁô¬ù§i¶D§Ú­Ì¨ä»ù­È¤£¬O¥u¬O7¡B8¶ôªÑ»ù¤ÏÀ³¡C
·|­û:dk10140377µoªí®É¶¡:2022/10/20 ¤W¤È 09:52:07²Ä2622½g¦^À³
¬Ý¤@¤UªÑ»ù´Nª¾¹D¤F~~

¤£¬O­«¤j§Q¦h «¢

¦pªG½Ã¹L140«e°ª´Nº}«G¤F

·|­û:¦V«e¦æ10140498µoªí®É¶¡:2022/10/20 ¤W¤È 09:08:02²Ä2621½g¦^À³
¬Ý³o¤½§iªº¤º®e

¦ü¥G«üªº¬O610

ÄÝ»D¤F

¤£¹L¦³°Ñ¥[¦~·|³ø§i

Á`ºâ¬O¤p§Q¦h

·|­û:dk10140377µoªí®É¶¡:2022/10/20 ¤W¤È 08:20:07²Ä2620½g¦^À³
³o¨½¦n§N²M~~§Oª©»¡³o¬O¸Ñª¼¦¨¥\¡AÅý§ÚÀ~¤F¤@¸õ

²r¤@¬Ý§Ú¥H¬°¬O±ÂÅv¤F

¦ý¦Ü¤Ö¤]ºâ¬O¦n®ø®§¤F

·|­û:Rock00910149258µoªí®É¶¡:2022/10/19 ¤U¤È 05:04:37²Ä2619½g¦^À³
1.¨Æ¹êµo¥Í¤é:111/10/19

2.¤½¥q¦WºÙ:ªYÄ£¥ÍÂåªÑ¥÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î

5.µo¥Í½t¥Ñ:

¥»¤½¥qªvÀø¡u«D°sºë©Ê¯×ªÕ¨xª¢¡v·sÃÄSNP-630¤Î¦³®Ä¥NÁª«¤§°Êª«¸ÕÅç¤Î¤G´Á¤HÅéÁ{§É

¸ÕÅç¨ãÅãµÛªº§Üµoª¢¤Î§ÜÅÖºû¤ÆÀø®ÄÀò2022¦~©ó¬ü°êªi¤h¹yÁ|¦æªº¡u¬ü°êÃľǮa¦~·|¡v

(AAPS 2022 PHARMSCI 360)±µ¨ü¨Ã©óªñ95°êªñ5000¾l¤H¤j·|¤¤¥¿¦¡µoªí¡C

6.¦]À³±¹¬I:¤£¾A¥Î

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

¤@¡BSNP-630ªvÀøªº¤p¹«ªº¨xµoª¢¡B¨x¯×ªÕÅÜ©Ê©MÅÖºû¤Æ±o¨ìÅãµÛ§ïµ½¡A¨äALT¤ô¥­¡B

ÅÖºû¤Æ¬ÛÃö¥Íª«¼Ð°O¡]§Yalpha-SMA¡BCol1a1¡BCol3a1©MTimp-1¡^§¡ÅãµÛ­°§C¡C

SNP-630©M¦³®Ä¥NÁª«³B²zªº¤p¹«ªº¨xŦ¤T»Ä¥Ìªoà­§t¶q§¡ÅãµÛ­°§C¡C¦bÁ{§É¸ÕÅ礤¡A

±µ¨üªvÀøªº±wªÌ¦b²Ä12¶g®ÉªºALT»P°ò½u­È¬Û¤ñ¦³ÅãµÛ­°§C¡A¨S¦³Æ[¹î¨ìÄY­«ªº¤£¨}

¨Æ¥ó¡C¦¹¥~¡ASNP-630¦³®Ä¥NÁª«ªí²{¥X§ÜÅÖºû¤Æªº¼ç¤O¡A¥]¬AÅãµÛ­°§CÅÖºû¤Æ¬ÛÃöªº

¥Íª«¼Ð°O(§YCCL4©MCCL5)¡C¦¹¥~¡AFibroScan´ú¶q¥çÅã¥Ü¨ä§ïµ½¨xÅÖºû¤Æªº¥\®Ä¡C

¤G¡BSNP-630ªº¦³®Ä¥NÁª«¤w§¹¦¨²Ä¤G´ÁÁ{§É¸ÕÅç°ª¡B§C¨â¾¯¶q²Õ¦@36¦W¨ü¸ÕªÌ¡A´Á¤¤

¤ÀªRµ²ªGÅã¥Ü¦bÁ{§ÉÀø®Ä«ü¼Ð»P¥¼ªAÃÄ«e¤ñ¸û¡A§e²{·¥ÅãµÛªvÀø®ÄªG¡A¦¨¥\¹F¦¨¦b¯×ªÕ

¨xª¢ªvÀø¤Wªº¥Ø¼Ð¡CSNP-630¥ç¤wÀò¥xÆWFDA®Ö­ã¶i¦æ¨Ã§¹¦¨Á{§É¤@´Á¸ÕÅç¡A¼Æ¾ÚÅã¥Ü

SNP-630¦b¤HÅé¤W¨ã¦³°ª«×¦w¥þ©Ê¡A¥Ø«e¥¿¿n·¥³W¹ºÁ{§É¤G´Á¡CSNP-630¬°ªvÀø¯×ªÕ¨xª¢

·s¦¨¤À·sÃÄ¡A°£¥»¨­ÃIJz¬¡©Ê§ó±j¥~¡ASNP-630¥t¦³4­Ó¥H¤W¬¡©Ê¥NÁª«¤w¦bÅ餺¸ÕÅç¤W

ÃÒ¹ê¥iªvÀø¯×ªÕ¨xª¢¥B¨ã°ª«×¦w¥þ©Ê¡A¥iª½±µ§@¥Î©ó¨xŦ¡A­°§C¨x¯×¡B¨xÅÖºû¤Æ¥Íª«¼Ð

°O¡AªvÀø¯×ªÕ¨xª¢¡C

¤T¡B¥»¤½¥q³z¹L§ë½Z°ê»Úª¾¦W¬ÛÃö»â°ì·|ij¤Î¬ì¾Ç´Á¥Z¡A±j¤Æ·sÃıڸsªº¾Ç³N»ù­È»P

°ê»Úª¾¦W«×¡C

¥|¡B¥Ø«e¡u«D°sºë©Ê¯×ªÕ¨xª¢¡v©|µL¼Ð·ÇªvÀøÃĪ«¡A¼ç¦b°Ó¾÷Ãe¤j¡ANASH¥«³õ¥¨¤j¡A

¥i¦P®É®e¯Ç¦h­Ó·sÃÄ¡C®Ú¾ÚGlobalData 2017¦~5¤ëªº³ø§i¹w´ú¡A¥]¬A¬ü°ê¡A¼Ú·ù¤­¤j°ê

®a¡]ªk°ê¡A¼w°ê¡A¸q¤j§Q¡A¦è¯Z¤ú©M­^°ê¡^©M¤é¥»ªºNASH¥«³õ¡A¦b¥¼¨Ó¤Q¦~ªº½Æ¦X¦~¼W

ªø²v¹F45¢H¡C¥t®Ú¾Ú¼w·N§Ó»È¦æ¤ÎEvaluate Pharmaªº¹w´ú¡A¥þ²yNASHÃĪ«ªº¥«³õ³W¼Ò

¦b2025¦~¤W¬Ý350»õ~400»õ¬ü¤¸¡C¥Ø«e¥»¤½¥q¥¿¿n·¥´M¨D»P°ê¥~¤j¼t¦@¦P¦X§@©Î±ÂÅvµ¥

¨Æ©y¡C

¤­¡B·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{­·ÀI¡A

§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

·|­û:dk10140377µoªí®É¶¡:2022/10/15 ¤U¤È 05:27:54²Ä2618½g¦^À³
¤U¬P´Á¤@¤S¬O¥[½X¤é
·|­û:½²ºû¤¯10143700µoªí®É¶¡:2022/10/15 ¤U¤È 01:27:36²Ä2617½g¦^À³
ªYÄ£¨xÃÄ­Y­n¤T´ÁÁ{§É¤]­n¨x¤t¶Ü¡HÁÙ¬O¥i¥H¥Î¨ä¥L¸û¤£«I¤J©ÊÀË´ú¡H
·|­û:½²ºû¤¯10143700µoªí®É¶¡:2022/10/15 ¤U¤È 12:18:06²Ä2616½g¦^À³
«O·ç²±¸³»¡²{¦b¤jÃļtÁÈ«D±`¦h²{ª÷¡A³º¤ñ¥«­ÈÁÙ°ª¡I¥L»{¬°®³³o¨Ç¿ú¨Ó¨ÖÁʤp¼t¦³¿ú³~¡I§Ú¸ÑŪ¤jÃļt¿ú¦h¹ïªYÄ£¬O¥¿¦V¡B¥Ø«eÀô¹Ò¤]«Ü¦n¡AªYÄ£µL¨xµÇ¬r§¹¬ü¯«ÃÄ¡B¨xÃIJĤ@¦W¡A­Y¯àÀò§Ö³q¡B¬ð¯}ªº¡A10­¿¥¼¨Ó¤£¬O¹Ú¡I
·|­û:¾¾¹À©OÎN¹À«¡10150521µoªí®É¶¡:2022/10/15 ¤W¤È 06:08:32²Ä2615½g¦^À³
CRO¦æ·~¤¶²Ð

read01.com/zh-tw/gRO8Axz.html#.Y0nbvnZByUl

¥þ²yTOP10 CRO¤¤¶È¦³ÃÄ©ú±d¼w©M Charles Riverªº¥D·~ÄÝ©óÁ{§É«eÃĪ«

¥D­n°¼­«©ó¦w¥þ©Êµû»ù

°²³]6634¬O¦W¨¬²y·s¨q¡A¨ü¥þ²y¤Q¤j»¨ªù²y¶¤¤¤¨â®a«C·ý¡A¥B¤w³q¹L«e¤Q¤j¸g¬ö¤½¥q¤Î²y±´´ú¸Õ³q¹L¡A

ñ¬ùª÷ªÖ©w¤£¨¥¥i³ë¡A´N«Ý®É¶¡´¦¾å¡C

·|­û:dk10140377µoªí®É¶¡:2022/10/13 ¤U¤È 01:57:23²Ä2614½g¦^À³
½²¤j¡A¤j®æ§½¡C

¤p§Ì¥u³Ñ¤U30%¥ª¥kÀò§Q¡A¤¤¶¡¦³¥X¤@¨Ç¡A³Ìªñ¤S¸É¦^§ó¦h¡C¤£¬O¯«µLªk¥X³Ì°ªÂI

¬Ý¬Ý³o110ªº©³¦³¨S¦³¼µ

¦ý¤½¥q¬£¦pªG¤£§V¤O½Í§P¡A¤j½L³o¼Ë®z¡A¤]¼µ¤£¦í~ÃD¥~¸Ü¡A©ñªÅªo³£ÁÈ¿ú¤F

³o2­Ó¤ë­Ó¤Hı±o¬O³Ì¦nªº®É¾÷¡A¤£­n©M¦X¤@¤@¼Ë¦Y¤F¬u³Ó¡A¥¼¤W¥«ÅܤW¥«¡C¾Ç°ê¤§¤j³»¡A¤T¤Ñ¨ì300¦h¦n¡C

==============================================================

¨ì¦~©³¦n®ø®§ÁÙ¬O¦³¡A©ú¦~¤@©w·|§ó¦n¡I6¨t¤]­n®É¶¡¬ã¨s¶i¦æ¡A§»Æ[¬Ý¤½¥q»ù­È§ë¸ê¡A©ú¦~³ø¹S²v·|¤ñ¤µ¦~°ª¡I©Z¥Õ»¡¨ì²{¦b¬°¤î¤µ¦~³ø¹S²v¤]¬ù4¦¨«Ü¤£¿ù¤F¡CÄ~Äò§a¡I

·|­û:½²ºû¤¯10143700µoªí®É¶¡:2022/10/13 ¤U¤È 12:58:04²Ä2613½g¦^À³
¨ì¦~©³¦n®ø®§ÁÙ¬O¦³¡A©ú¦~¤@©w·|§ó¦n¡I6¨t¤]­n®É¶¡¬ã¨s¶i¦æ¡A§»Æ[¬Ý¤½¥q»ù­È§ë¸ê¡A©ú¦~³ø¹S²v·|¤ñ¤µ¦~°ª¡I©Z¥Õ»¡¨ì²{¦b¬°¤î¤µ¦~³ø¹S²v¤]¬ù4¦¨«Ü¤£¿ù¤F¡CÄ~Äò§a¡I
·|­û:ROGER588910148151µoªí®É¶¡:2022/10/11 ¤U¤È 09:21:17²Ä2612½g¦^À³
²Ä1¤äTHR£]¿E°Ê¾¯¬ÝResmetirom.

SNP-610´Á¤¤¤ÀªR...ªì¨B¼Æ¾ÚÀu©óResmetirom.

--------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/7 ¤W¤È 11:26:27²Ä 2199 ½g¦^À³

MGL-3745¼g¿ù§ï¥¿¦¨MGL-3196(Resmetirom)¡C

2022.7.5 ¤û¬z¤j¾Ç¨x¯f¾Ç«È®y±Ð±Â´µ¸¦ªâ«¢¨½´ËÂå¾Ç³Õ¤h: Resmetirom¡§¦³¥i¯à¦¨¬°²Ä¤@­Ó³Q§å­ã¥Î©ó NASH ±wªÌªºÃĪ«¡¨

-------------------------------------------------------------------------------------------------

µ²½×:

³Õ¤h¨S»¡ªº¨Æ¡AResmetirom¬O§_¯u¯à¦¨¬°²Ä¤@­Ó³Q§å­ã¥Î©ó NASH ±wªÌªºÃĪ«¡AÃöÁä¦b¦~©³ªºÅ]¤ýÃö¥d¨x¬ïµ²ªG¦p¦ó?(¤T´Á±o­n¨x¬ïLiver Biopsy)

-------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/3 ¤W¤È 06:27:54²Ä 2169 ½g¦^À³

¬°¤°»ò¥s¹Ú´K¥H¨Dªºµª®×???

.....

SNP-610´Á¤¤¤ÀªR...ªì¨B¼Æ¾ÚÀu©ó:Ocaliva , MGL3196(Resmetirom¡^, Selonsertib

·|­û:dk10140377µoªí®É¶¡:2022/10/11 ¤U¤È 08:12:29²Ä2611½g¦^À³
r¤jÂI¥X­«ÂI¡A¦V¦Ì°êªºAkeroªÑ»ùÁÚ¶i¡AÁöµM»¡ªº«Ü¤ßµê(¹ï¤ñ¤µ¤Ñªº»ù¿ú)

·|­û:ROGER588910148151µoªí®É¶¡:2022/10/11 ¤U¤È 06:39:39²Ä2610½g¦^À³
§Ú¤§«e1¤Ñ1ÁûPPIªvÀø­G¼ìºÅ¡A´X¥G¨S·Pı¨ì°Æ§@¥Î¡A¦Y¤F6­Ó¤ë¤w·Q°½Ãi¤£¦Y!

NASHºC©Ê¯f¡A±wªÌÄ@·Nªø´Á§Ô¨ü·kÄo/äú¤ß¤Ï­G/¸¡Âmµ¥°Æ§@¥Î???

·|­û:ROGER588910148151µoªí®É¶¡:2022/10/11 ¤U¤È 05:47:01²Ä2609½g¦^À³
THR£]¿E°Ê¾¯ASC41 [52¶g] VS. Akero FGF21ªvÀø¶g´Á[24¶g] VS. SNP-610/630À³¸Ó¬O·|±q[12¶g]©Ôªø[24¶g]?

Áö¬OºC©Ê¯f¡A¦ý52¶g¤Ó¤[¨o!

--------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2021/11/26 ¤W¤È 09:10:39²Ä 1486 ½g¦^À³

2019/06/27

¤u°Ó§ù¿·»T

ªYÄ£¥ÍÂå¡]6634¡^27¤é«Å¥¬¡AºX¤U­«½S¡u·s¤Æ¾Ç¦¨¥÷¡vªvÀø«D°sºë©Ê¯×ªÕ¨xª¢(NASH)²Ä¤G¥N·sÃÄSNP-630¡AÄ~¨ú±o«n«Dµo©ú±M§Q«á¡A¦AÀò±o¬ü°ê±M§Q¡A¦¹±M§Q¦³®Ä´Á­­©|¦³17¦~¡A³Ì¦h¥i©µªø¦Ü2041¦~¡A¹ï©ó¥¼¨Ó±ÂÅv¦³¨M©w©Ê¼vÅT¡C

...¥Ø«e¤w§¹¦¨¤»¶µ¤HÅéÁ{§É¸ÕÅç¡C¶i¦æ¤¤ªºSNP-6¨t¦C¶}©ñ¦¡Á{§É¤G´Á¬ã¨s¤wÀò±oÅãµÛ¤HÅéÀø®ÄÃÒ¾Ú¡C¾Ú´Á¤¤¤ÀªRµ²ªG¡A NASH¸ÕÅç²Õ¡A¸g [12¶g] ªvÀø«á¡A¨x¥\¯àÀø®Ä«ü¼Ð¤è­±¡G¾¢Ói»Ä¤þ଻ÄÂà®ò°ò»Ã¯À(ALT)¡B¾¢Ói»Ä­f¾L»ÄÂà®ò°ò»Ã¯À(AST)¡B¨Å»Ä²æ²B¡]¨»¨C¡^¡]LDH¡^ÅãµÛ­°§C¨ÃÀu©ó«eªu¤j¼tªºÁ{§É¤G´Á¬ã¨sµ²ªG¡F

-------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2020/8/20 ¤U¤È 01:49:07²Ä 299 ½g¦^À³

ª`·N¹Ïªí®É¶¡¶b:SNP-610¬OªvÀø [12¶g ] AST¡BALTÅãµÛ¤U­° / Ocaliva ¬O18­Ó¤ë¡C

©Ò¥H....

·|­û:dk10140377µoªí®É¶¡:2022/10/11 ¤U¤È 04:25:42²Ä2608½g¦^À³
­n¥[ªo

ºq§«Å§GTHR£]¿E°Ê¾¯ASC41ªvÀø¨x¬ï¬¡ÀËÃҹꪺ«D°sºë©Ê¯×ªÕ©Ê¨xª¢52©PII´ÁÁ{§É¸ÕÅ秹¦¨­º¨Ò±wªÌµ¹ÃÄ

ASC41¬OÁ{§É¶i«×¤¤°ê²Ä¤@¡B¥þ²y²Ä¤Tªº¥Î©ó«D°sºë©Ê¯×ªÕ©Ê¨xª¢(NASH)ªº¥Òª¬¸¢¿E¯À¨üÅé£] (THR£])¿E°Ê¾¯­Ô¿ïÃĪ«¡CASC41 II´ÁÁ{§É¸ÕÅç¬O¥Ñ¤¤°ê¥Íª«§Þ³N¤½¥qµo°_ªº¥Ø«e¶i®i³Ì§ÖªºÀøµ{¬°52©P¤J²Õ¨x¬ï¬¡À˹êNASH±wªÌªºII´ÁÁ{§É¸ÕÅç

·|­û:½²ºû¤¯10143700µoªí®É¶¡:2022/10/11 ¤W¤È 11:24:09²Ä2607½g¦^À³
³o¨â®a¦³«e¨Ò¥i´`¡A»P§O®a¤½¥q¨xÃij¡¤À±q¦X§@¨óij¨ìñ±ÂÅv¬Û¶Z3¦~¡A810¥Ø«e§Ö2¦~¤F¤]¬O¥¿±`¡C6¨tµL½×ªá¸¨½Ö®a¹ïªÑªF³£¬O¤j§Q¦h¡C
·|­û:½²ºû¤¯10143700µoªí®É¶¡:2022/10/10 ¤W¤È 11:30:43²Ä2606½g¦^À³
¨S¨Æ´N¤@ª½¤ÏÂЬݫe¤å¡A¤j¥b¬Or¤j±M¤å¡F­ì¨Ó¼b¥Í¤]¬O¹ï¨xÃĦ³¿³½ì¡A¨ºªYÄ£¨xÃÄ6¨t±ÂÅv¤]©M³o¨â®a¦³Ãö«Y¡IºÝ¬Ý¥X»ù¦p¦ó¨M©wµ¹½Ö¡A¬JµM­ÇÃĤ@¨Ö±ÂÅv¡AÅܲ§©Ê´N¬O¤À°Ï»P¥þ²y¨âºØ¡C
·|­û:½²ºû¤¯10143700µoªí®É¶¡:2022/10/10 ¤W¤È 10:46:05²Ä2605½g¦^À³
¬Ýr¤j«e¤ågskËß10»õ¬ü¤¸»P¤@®a¨xÃĬãµo¤½¥q¦X§@¡i2021¡B11¡j¡A¥i¨£g¹ï¨xÃĬO¦³¿³½ìªº¡FÂX¤j¦X§@¥i¯à´N¬O¨xÃÄ6¨t¡C
·|­û:ROGER588910148151µoªí®É¶¡:2022/10/9 ¤U¤È 12:21:14²Ä2604½g¦^À³
ªYÄ£¥u»EµJ[¨x¯f]·sÃĬãµo¡A¸£Àù»P¨ä¥L¾AÀ³¯g±o¬ÝLicense-inÃļtªº·NÄ@!

Àù¯g¥ÎÃĪ«¦hµLªk³q¹L¦å¸£«Ì½ª¡A¦]¦¹¡A¥i¥Î©óªv療¸£¸~½Fªº¤Æ療ÃĪ«¨ü¨ì·¥¤jªº§½­­¡C

------------------------------------------------------------------------------------------------

scitechvista.nat.gov.tw/Article/C000003/detail?ID=5026001f-55bb-4855-acc8-7e93b40624b8

¹Í¹Í¹Í¡I²Óµß¤Å¶i¡I³o¸Ì¬O¤j¸£ªºµ´¹ï¨¾¿m¡X¡X¦å¸£«Ì»Ù

¤HÅé§ó¾Ö¦³¡u¤T¤j«Ì»Ù¡v¡A©{¦p°í©T«°Àð¡A¯à©è¾×¥~¬É²§ª«ªº§ð¤J¡C¤T¤j«Ì»Ù¥]¬A­L½L«Ì»Ù¡B¸z¹D«Ì»Ù»P¡u¦å¸£«Ì»Ù¡v¡]©ÎºÙ¦å¸£»Ù¾À¡Ablood¡Vbrain barrier¡ABBB¡^¡A¨ä¤¤¡A¦å¸£«Ì»Ù³Ì¬°½ÆÂø¡C

·|­û:½²ºû¤¯10143700µoªí®É¶¡:2022/10/9 ¤U¤È 12:09:21²Ä2603½g¦^À³
±w¤@ª½¦Y´¶®³¯k¦n¤F¤j¥b¡Ar¤j³o¸ê°T¦³ÃСI3196¬O¨xÃÄ«e½ú¡A¥u¦³¤@­Ó¾÷Âà¡A6¨t¦³2­Ó¾÷Âà®ÄªG§óÀu¡IªYÄ£­Y¯à¬ãµoÀùÃĪ«¡A¦pªê²KÁl¡I
·|­û:½²ºû¤¯10143700µoªí®É¶¡:2022/10/9 ¤W¤È 11:44:32²Ä2602½g¦^À³
¤AñQ¦w×ô¨ã®øª¢±þµß¥\¯à¡A«e¤å¦³½Í¨ì¤@¦ì¡@Àù
·|­û:ROGER588910148151µoªí®É¶¡:2022/10/9 ¤W¤È 10:57:54²Ä2601½g¦^À³
SNP-810±ÂÅv»ù­È???(¤îµhÃÄ+Àù¯g¥«³õ)

1.¤U¦C¸ÕÅç¥HSNP-810¥i´£°ª¾¯¶q¡A¸ÕÅçµ²ªG???

2.SNP-610/630»PSNP-810ªvÀø¸£Àù¡A¨ã¦³¥[­¼®ÄÀ³?

www.turkishneurosurgery.org.tr/pdf/pdf_JTN_2427.pdf (¬Ý¹Ïªí´N¤@²M¤G·¡)

¬ã¨sµ²ªGªí©ú¡A¼³¼ö®§µh¹ï½¦½è¥À²Ó­M½F²Ó­M¨ã¦³§Ü¸~½F§@¥Î¡A³oºØ¬¡©Ê¬O¥Ñ¤£¦Pªº«H¸¹³q¸ô»¤¾É¡C

-----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2021/4/27 ¤W¤È 10:07:08²Ä 1066 ½g¦^À³

SNP-610/630»PSNP-810ªvÀø¸£Àù???

---------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2021/4/27 ¤W¤È 09:53:44²Ä 1065 ½g¦^À³

DGAT1¬O¤@个«D±`¦³§Æ±æªv疗恶©Ê胶质¥À细­M½F(¤@ºØ³Ì±`¨£¤]¬O³Ì¨ã«Iŧ©Êªº¸£Àù)ªº·sªº药ª«¹v点¡C

------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2021/4/14 ¤W¤È 09:08:28²Ä 1026 ½g¦^À³

2020.10.26¼³¼ö®§µh¹ï½¦½è¥À²Ó­M½F²Ó­M¼W´Þªº¼vÅT

www.turkishneurosurgery.org.tr/pdf/pdf_JTN_2427.pdf

µ²½×¡G§Ú­Ìªº¬ã¨sµ²ªGªí©ú¼³¼ö®§µh¹ï½¦½è¥À²Ó­M½F²Ó­M¨ã¦³§Ü¸~½F§@¥Î¡A¨Ã¥B³oºØ¬¡©Ê¬O

¥Ñ¤£¦Pªº«H¸¹³q¸ô»¤¾É¡C...§Ú­Ìµo²{¼³¼ö®§µh´î¤Öªº²Ó­M¼W´Þ¨ú¨M©ó [¾¯¶q]©M[«ùÄò®É¶¡]....

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶

·|­û¡GROGER588910148151 µoªí®É¶¡:2021/4/27 ¤W¤È 09:53:44²Ä 1065 ½g¦^À³

DGAT1¬O¤@个«D±`¦³§Æ±æªv疗恶©Ê胶质¥À细­M½F(¤@ºØ³Ì±`¨£¤]¬O³Ì¨ã«Iŧ©Êªº¸£Àù)ªº·sªº药ª«¹v点¡C

2020.8.4

www.x-mol.com/news/457072

ªñ¤é¡A¬ü国«X¥è«X¦{¥ß¤j学肿½F¤¤¤ß³¢¼w¨}±Ð±Âªº¬ã¨s团队¡A¥Hµ{²»³Õ¤h©M¯Õ®p³Õ¤h为¦}¦C²Ä¤@§@ªÌ¦bCell Metabolism杂§Ó¤W发ªí题为¡§Targeting DGAT1 ameliorates glioblastoma by increasing fat catabolism and oxidative stress¡¨ªº¬ã¨s论¤å¡A该¬ã¨s­º¦¸´¦¥Ü调节¯×ªÕ»Ä储¦s酶¡X¡X¤G酰°ò¥Ìªo-酰°ò转²¾酶¡]DGAT1¡^¡X¡X¬O¤HÊ^恶©Ê胶质¥À细­M½F关键ªº¯×质¥­¿Å调节¦]¤l¡A¦}´¦¥ÜDGAT1¬O¤@个«D±`¦³§Æ±æªv疗恶©Ê胶质¥À细­M½Fªº·sªº药ª«¹v点¡C

该¬ã¨s­º¦¸´¦¥Ü¤F¥Ìªo¤Tà­©MDGAT1¦b胶质¥À细­M½F¯f¤H组织标¥»¤¤°ªªí达¡A¥BDGAT1ªºªí达¶qÉO¯f¤Hªº¾ãÊ^¦s¬¡时间§e负¬Û关¡]图1¡^

·|­û:dk10140377µoªí®É¶¡:2022/10/8 ¤U¤È 04:39:49²Ä2600½g¦^À³
§^¤£¥Î¾á¤ß®Ö¼u ¬Ý¬Ýªo»ù opec+«X°ê¤~¬O³Ì¤j¨ü¯qªÌ §Ú¬O½ä¦Ì°ê²]°Õ~~©ñªÅ¥ÛªoÁ«¦º¤F

¯u´±¥´ ¤£¥uªÑ»ù ­ìª«®Æ¤]gg ªo»ùÁÙupup

¤Ï¥¿§Ú¨S©Ð ¨S¿ú ­«·sÂk0¨Ó»¡ ¤@°_­«·s¥Xµo==>§Æ±æ¤pÄ£Åý§Úfire

´«¥y¸Ü¸Ü ¯u¥´¤F ¤îµhÃĤ]­n½æ¨ì¤£­n¤£­n

¤Ï¥¿¬P´Á¤@¨Ó¬Ý¬Ý¥Í§Þ¹ï¤j½L ½Ö²]Àú

=============================================================================

¤pÄ£¤£¬O¤¤¤Ñ¤jÀY¤]¦n ¤£µM·|­«ºt®±²±³Q¤Õ©ú¦Y¤Fªºµ²§½

·|­û:ROGER588910148151µoªí®É¶¡:2022/10/8 ¤U¤È 01:21:09²Ä2599½g¦^À³
³Ì²×ÁÙ¬O¥X²{§Ú³Ì¾á¼~ªº®Ö¼u«Â¯Ù!!!

------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/2/22 ¤W¤È 10:55:27²Ä 1725 ½g¦^À³

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/2/17 ¤U¤È 12:34:46²Ä 1710 ½g¦^À³

§Ú¥H¬°¬O¥Ñ«Xù´µ¶}¤õ¤ÞÃz¡Aµ²ªG¯Q§JÄõª¯¥M¤H¶Õ¡AºÆª¯¥ý«r¤H!

------------------------------------------------------------------------------------------------

´Á±æ¥_·¥ºµ´¶¤B¦b¥Ï¤FºÆª¯2­Óºµ´x«á±¼ÀY´N¨«¡A¤£µM...«u

·|­û:ROGER588910148151µoªí®É¶¡:2022/10/8 ¤U¤È 01:11:06²Ä2598½g¦^À³
2022.10.7 À³¹ï®Ö¾Ô«Â¯Ù¡H¬ü°ê«æ±ÄÁÊ¡u92»õ¿ç®g¯fÃĪ«¡v

¬ü«X¤À¶Ç¤j¶q±ÄÁÊ¿ç®g¯fÃĪ«¡B¸K¤ù

------------------------------------------------------------------------------------

¯u®ÖÃz ºG ºG ºG

¤Ñ¦ö¸Uª«¥ÍÆF!

·|­û:ROGER588910148151µoªí®É¶¡:2022/10/8 ¤U¤È 12:57:50²Ä2597½g¦^À³
µÇ¬r©Ê!

¨ì 2030 ¦~¡A¥þ²y«Dªü¤ùÃþÃĪ«¯kµhªvÀø¥«³õ³W¼Ò±N¹F¨ì 779.1 »õ¬ü¤¸

www.grandviewresearch.com/press-release/global-non-opioid-pain-treatment-market

2022 ¦~ 9 ¤ë¡A¬ü°ê FDA «Øij¦bÃh¥¥ 20 ¶g®ÉÁקK¨Ï¥Î«Dªü¤ùÃþÂíµh¾¯ªvÀø¡A¦]¬°¥¼¥X¥ÍÀ¦¨à¥X²{µÇŦ°ÝÃDªº¥i¯à©Ê«Ü°ª¡C¬F©²ªº¦¹ÃþÁ|±¹¥i¯à·|­­¨î«DÍrÅé§Üª¢ÃĪº³B¤è¡A±q¦Ó­­¨î«Dªü¤ùÃþÃĪ«¯kµhªvÀø¥«³õªº¼Wªø¡C

¬F©²ªº¦¹ÃþÁ|±¹¥i¯à·|­­¨î«DÍrÅé§Üª¢ÃĪº³B¤è

¬F©²ªº¦¹ÃþÁ|±¹¥i¯à·|­­¨î«DÍrÅé§Üª¢ÃĪº³B¤è

·|­û:ROGER588910148151µoªí®É¶¡:2022/10/8 ¤U¤È 12:49:14²Ä2596½g¦^À³
µÇ¬r©Ê!

2020.10.15 FDAµo¥¬ÃĪ«¦w¥þĵ°T

www.fda.gov/media/142967/download

¬ü°êFDAµo¥¬Äµ°T¡A§³®W20¶g¥ª¥k©Î§³®W«á´Á¨Ï¥Î«DÃþ©T¾J§Üµoª¢ÃÄ¡]NSAIDs¡^®£¾É­P­L¨à¨u¨£¦ýÄY­«ªºµÇŦ°ÝÃD¡A¶i¦Ó¤Þµo¦Ï¤ô¹L¤Ö©M§³®W¨Öµo¯g¡AÀ³ÁקKªA¥Î¡C

«DÍrÅé§Üª¢Ãijq±`¥Î©ó½w¸Ñ¯kµh©M°h¿N¡C¥¦­Ì¥]¬Aªü¥q¤ÇªL¡B¥¬¬¥ªâ¡B萘´¶¥Í¡BÂù´âªâ»Ä©M¶ë¨Ó©õ¥¬µ¥ÃĪ«¡C

--------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/9/1 ¤U¤È 08:52:35²Ä 2370 ½g¦^À³

SNP-810µLµÇ¬r©Ê³o­ÓÀuÂI¡A¹ï©ó·m§ðNSAIDs¡]«DÃþ©T¾J®øª¢¤îµhÃÄ¡^ªº¥«³õ¥÷ÃB¤j¦³§U¤O!

¤îµhÃį}ÃaµÇŦ«OÅ@¾÷¨î!!!

www.commonhealth.com.tw/article/74087

½Ð·V¥Î¤îµhÃÄ¡IµÇŦ¬ì¦WÂå¨Iµh§i¥Õ

·|­û:ROGER588910148151µoªí®É¶¡:2022/10/8 ¤W¤È 10:31:22²Ä2595½g¦^À³
¬Q¤Ñ¬üªÑ±Y2.11%(630ÂI)¡A8+9¯««i¦Aöt+9.57%(¬ð¯}9/13°ª)¡AFGF21ÃĪ«¸Þ²§¦a1¤Ñ!

-----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/9/14 ¤W¤È 06:16:17²Ä 2463 ½g¦^À³

¬üªÑ±Y¶^3.94% VS. NASH·§©ÀªÑÃzº¦:Akero (+136.76%) / 89bio Inc(+40%)

«Ü¤£´M±`ªº1¤Ñ.

·|­û:dk10140377µoªí®É¶¡:2022/10/8 ¤W¤È 08:11:04²Ä2594½g¦^À³
³£¦³³\¥i¤F ÁÙ¤£­»¶Ü?

¨ì©³¦bµ¥¤°»ò ¥xªÑ¬P´Á¤@¤S­n³Q¬üªÑ¸õ¤ô¼v¦V ¤pģģ·|¤£·|¶^¯}120©O??

=============================================

¦³¤@¨Æ¤@ª½¤£¸Ñ¡G¸³¨Æªøªí¥Ü¡A¸Ó¤½¥q¶}µoªºµL¨x¬r©Ê¤AñQÓi×ô¤îµh·sÃÄSNP-810¡AÀò¬ü°êOTC monograph³\¥i¡A¤w¨ú±oNational Drug Code¡]°ê®aÃÄ«~ÅçÃÒ¸¹¡^¤Î¬ü°ê¥«³õ¾P°â¸ê®æ¡C

¤jÃļt±ÂÅvª÷°ª¡A¾P°â¶q¤j¤S¯à°¨¤W¥Î­ì¨ÓÃÄÃÒÄ~Äò¾P°â¡Aµ¥·sÃÒ¤U¨Ó¦A´«ÃÒ¡A¤À¼íª÷¤]°¨¤W¦³¡A³o¬O¤½¥q±ÂÅv­º¿ï²{¦b¦X§@¤j¼t­ì¦]¡F¬Û«H©¼¦¹¦X§@¨Ã¥BÂX¤j¦X§@¤~¬OºÍ´¼¡C

·|­û:½²ºû¤¯10143700µoªí®É¶¡:2022/10/7 ¤U¤È 11:57:26²Ä2593½g¦^À³
¤jÃļt±ÂÅvª÷°ª¡A¾P°â¶q¤j¤S¯à°¨¤W¥Î­ì¨ÓÃÄÃÒÄ~Äò¾P°â¡Aµ¥·sÃÒ¤U¨Ó¦A´«ÃÒ¡A¤À¼íª÷¤]°¨¤W¦³¡A³o¬O¤½¥q±ÂÅv­º¿ï²{¦b¦X§@¤j¼t­ì¦]¡F¬Û«H©¼¦¹¦X§@¨Ã¥BÂX¤j¦X§@¤~¬OºÍ´¼¡C
·|­û:dk10140377µoªí®É¶¡:2022/10/7 ¤U¤È 09:50:13²Ä2592½g¦^À³
ªGµM¬O¤j®æ§½¡A³£µ¥¤F¤G¦~¤F¡AÁÙ®t¤T­Ó¤ë´N¦~©³¡A¾Ç°ê³»¥h¦~º²Â_¤@¤U¤T¤Ñ ª½¹F300

¥¢¥hªº¦b·sÃÄ®³¦^¨Ó

·|­û:½²ºû¤¯10143700µoªí®É¶¡:2022/10/7 ¤U¤È 07:39:37²Ä2591½g¦^À³
¹ï¤½¥qµL¨xµÇ¬r§¹¬ü¯«ÃÄ­n¦³«H¤ß¡I±ÂÅv®×·mµÛ­n¤£¥²¾Þ¤ß¡A¤½¥q¥²µM·|¥H¤½¥q¦³§Q±¡ªp½Í§P¡A¦n¨Æ¦b¦~©³«e·|¥X²{¡AÁ`¬O³oºØ·Pı¡C
·|­û:dk10140377µoªí®É¶¡:2022/10/7 ¤U¤È 03:03:33²Ä2590½g¦^À³
ǢǢ

ªGµM¬O¼ÐÃD¸Ø¤jÂI´N¦³¤HÃö¤ß

§^¥i¨S»¡¤°»ò¤½¥q¤°»òÃıÂÅv¨S¹L®@?????¤]¨S¹ï»ùÃö¨t ¤]¨S¤ºÀ`

±ÂÅv¨S¹L==>§Ö°k§a ¥i¥Nªí©È¨S¹L¨S±ÂÅv´N§Ö½æ ¨S«H¤ß¤]´N½æ ¦³«H¤ß´N¥[½X ¾A¥Î¦b¨C¤@­Ó²£·~¨C¤@­Ó¤½¥q

ÁÂÁ´£¿ô ²q¤@²q¤£¥Çªk§a ¬Ý¤F¤j¶^ ¤ß±¡¤£¦n ©`¦Ì¤á¤Ö¤F¼Æ¤Qw ³oªO¤Ó§N²M¤£¹³¥_·¥ ¤£¦nª±§r

¥u­n§OªºªO¤j ¤£­n¶Ãcue ´N¨S¨Æ

·|­û:¦V«e¦æ10140498µoªí®É¶¡:2022/10/7 ¤U¤È 02:40:37²Ä2589½g¦^À³
dK¤j

±ÂÅv¨S¹L¡H

¤½¥q¨S¦³¤½§i

§O³yÁÁ¡H

¦pªG¬O±z©ñ°²°T®§¡H

¥i¯à·|¦Y¤W©x¥q¡H

·|­û:dk10140377µoªí®É¶¡:2022/10/7 ¤U¤È 02:26:23²Ä2588½g¦^À³
±ÂÅv¨S¹L==>§Ö°k§a

Ä@½äªA¿é

¤p¶R¤@ÂI

³o­Ó¶q 100±i´N©Ô¤F¤@¥b

=======================

ªY ¤µ¤Ñµo¥Í¤F¤°»ò🤔

·|­û:©ú¤é´¸10152496µoªí®É¶¡:2022/10/7 ¤U¤È 01:56:00²Ä2587½g¦^À³
²ö©ú+®£·W+¦@¦ñ=¤j¶^¡H

¤µ¤Ñ´N¾ß´X±i°_¨Ó¦s©ñ

·Q­n§Úªº²¼¶Ü¡H

µ¹§Ú±ÂÅv¨ä¾l§K½Í¡C

·|­û:ªiªi10151449µoªí®É¶¡:2022/10/7 ¤U¤È 01:16:02²Ä2586½g¦^À³
ªY ¤µ¤Ñµo¥Í¤F¤°»ò🤔
·|­û:dk10140377µoªí®É¶¡:2022/10/6 ¤W¤È 09:20:32²Ä2585½g¦^À³
·sÃij洫³o¤ä ¤W¬Ý800?

«¢«¢ ³o´N¬O¦Ì°ê¸ê¥»¥«³õªº§Q®`

¤£¦p§Ú­Ì´X­Ó©`¦ÌªÑ§ë²¼Åý·sÃĤU¥«(¾Ç¥x·L)¥h¦Ì°ê§a

=================================================

Akero¦b2017¦~³Ð¥ß¡A­û¤u37¤H¡A 9/13Ãzº¦¦¬29.05¡A¬Q¤é¦¬38.31(³Ð·s°ª)¡A¥«­È17.78»õ¬ü¤¸¡C

akerotx.com/pipeline/

pipeline´N1¤äÁ{§É¤G´ÁNASHÃĪ«Efruxifermin ¡A§OµL¥Lª«!

·|­û:ROGER588910148151µoªí®É¶¡:2022/10/6 ¤W¤È 08:12:48²Ä2584½g¦^À³
NASH¥«³õ§lª÷¾y¤OµLªk¾×!

Akero Therapeutics «Å¥¬§¹¦¨ÂX¤j´¶³qªÑ¤½¶}µo°â2.3»õ¬ü¤¸(9/15´£¥æ9/19§¹°â)

ir.akerotx.com/news-releases/news-release-details/akero-therapeutics-announces-closing-upsized-public-offering-0/

2022¦~9¤ë15¤é¦V¬ü°êÃÒ¨é¥æ©ö©e­û·|´£¥æ¤F»Pµo°â±ø´Ú¬ÛÃö©M´y­zªº³Ì²×©ÛªÑ»¡©ú®Ñ¸É¥R©MÀHªþ©ÛªÑ»¡©ú®Ñ¡C

·|­û:ROGER588910148151µoªí®É¶¡:2022/10/6 ¤W¤È 08:01:26²Ä2583½g¦^À³
2022.8.1 ¡m¬húí¤M¡n¤l¥Z³Ì·s发¥¬¡G¥þ²y¨C3个¦¨¤H´N¦³1¤H¿©±w¯×ªÕ¨x

www.163.com/dy/article/HDNED9TI05349C3G.html

...¥þ²y­S围内¡A«D°sºë©Ê¯×ªÕ©Ê¨x¯fªº±w¯f²v³£§e现¥X³v渐¼W°ªªº趋势

---------------------------------------------------------------------------

¯×ªÕ¨x¤£¬O¯f-->¦ý¯fÅܬ°¯×ªÕ¨xª¢´N¥i¯à­n±zªº©R(¨xŦ³QºÙ¬°¡u¨IÀqªº¾¹©x¡v¡ANASHªì´Á¨S¬Æ¯gª¬¡A±wªÌÃø¥Hµoı¨x¥X°ÝÃD)-->¦A¯fÅܦ¨¨xÅÖºû¤Æ(F1~F3)»P¨xµw¤Æ(F4)´N¬O­n±zªº©R!

·|­û:ROGER588910148151µoªí®É¶¡:2022/10/6 ¤W¤È 07:03:15²Ä2582½g¦^À³
Akero¦b2017¦~³Ð¥ß¡A­û¤u37¤H¡A 9/13Ãzº¦¦¬29.05¡A¬Q¤é¦¬38.31(³Ð·s°ª)¡A¥«­È17.78»õ¬ü¤¸¡C

akerotx.com/pipeline/

pipeline´N1¤äÁ{§É¤G´ÁNASHÃĪ«Efruxifermin ¡A§OµL¥Lª«!

------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/9/13 ¤U¤È 10:09:04²Ä 2458 ½g¦^À³

¥Ø«e¬üªÑ¤j¶^ VS. NASH·§©ÀªÑÃzº¦:Akero (+160%) / 89bio Inc(+46%)

------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/9/30 ¤U¤È 10:17:26²Ä 2573 ½g¦^À³

.Akero¦Aº¦13%+³Ð¤µ¦~°ª¡A£¯£¯£¯¡A¶Â¥Õ­¦§g¥X³õ¤f¥Õ:§O¤Hªº¥¢±Ñ´N¬O§Úªº§Ö¼Ö?

·|­û:½²ºû¤¯10143700µoªí®É¶¡:2022/10/3 ¤U¤È 04:33:42²Ä2581½g¦^À³
ªYÄ£­°¯×ªÕ¨xª¢ÃÄÃĮĺâ²Ä¤@¦W¡A±Æ«e­±4Áû¤¤¡A¤@Áû¥¢±Ñ¤@ÁûÂà¦V³Ñ2Áû¡A³o2Áû­Y¦¨¥\¤]¤£¼vÅTªYÄ£µo´§¡A­Y¥¢±Ñ¨ºªYÄ£Åܦ¨¤Ñ¤§Åº¤l¡F¥Ø«e¨xª¢ÃijæÁû¶ÈÁ{§É«e´N­n7»õ¬ü¤¸±ÂÅv¡A«¥ªYÄ£¼Æ¾Ú¦n¨ã°sºë«D°s©Ê¨xª¢¬Ò¯à¾A¥Î¡B¥¥°ü¤]¦æ¡A2Áû¤@¨Ö±ÂÅv15»õ¬ü¤¸¥H¤W¡A­Y®³¬ð¯}¸ê®æ¦A¥[5»õ¬ü¤¸¡CªYÄ£«eµ{¦üÀA¡I¥[ªo¡I
·|­û:ROGER588910148151µoªí®É¶¡:2022/10/3 ¤W¤È 09:14:59²Ä2580½g¦^À³
1.¥x·LÅéTLC599 ¤G´Á: clinicaltrials.gov/ct2/show/NCT03005873?term=TLC599&draw=2&rank=3

Experimental: TLC599 LD group:12 mg DSP with 100 µmol PL (1.0 mL)

Experimental: TLC599 HD group:18 mg DSP with 150 µmol PL (1.5 mL)

Placebo Comparator: 1.5 mL normal saline

2.¥x·LÅéTLC599 ¤T´Á:

Experimental: TLC599:TLC599 (1mL) IA injection

Active Comparator: Dexamethasone sodium phosphate 4mg (1mL) IA injection

Placebo Comparator: Normal saline (1mL) IA injection

--------------------------------------------------------------------------------------------

TLC599¤D¥x·LÅé¿W®a[ªø®Ä½wÄÀ]°t¤è¤§¦a¶ë¦ÌªQÁC»Ä¶uÃĪ«(Dexamethasone sodium phosphate)

ÃĪ«¥Øªº¦bÅçÃÒ6­Ó¤ëªº[ªø®Ä½wÄÀ]®ÄªG¡A«ç»ò¤£¦b¤G´ÁÁ{§É´N¥ÎDexamethasone sodium phosphate°µ¹ï·Ó?

·|­û:¶ø¥ì´µ¯S10031727µoªí®É¶¡:2022/10/2 ¤U¤È 04:18:45²Ä2579½g¦^À³
¥x·LÅé TLC599 Ãö¸`ª¢¤î¯kµhÃÄÁ{§É¤T´Á¥½¹FÅãµÛ®ÄªG! 6.7E ¬üª÷±ÂÅvª÷¦¨®£¦¨ªw¼v¡C

Endo says osteoarthritis pain candidate failed in late-stage study

seekingalpha.com/news/3886056-endo-says-osteoarthritis-pain-candidate-failed-in-late-stage-study

·|­û:½²ºû¤¯10143700µoªí®É¶¡:2022/10/2 ¤U¤È 02:00:45²Ä2578½g¦^À³
®ø¤Æ¹D¬ï¬}¥¬¬¥ªâ¡A¨â¨t¦³6¦Ê»õ¬ü¤¸¥i¥H·m§ð¡C­Y¤@¦Ê»õ¬ü¤¸¥«¦û¤@¦¨¤À¼íª÷¨CªÑ400¤¸Ã¬§Q¡C±ÂÅv¶V«á·|¶V°ª¤£¥²«æ¡C¹q¸£®t¯u©êºp¡I
·|­û:½²ºû¤¯10143700µoªí®É¶¡:2022/10/2 ¤U¤È 01:38:58²Ä2577½g¦^À³
ªYÄ£8¨tµLµÇ¬r©Ê¤w®Ê¤É¬°§¹¬ü¯«ÃÄ¡IÀ£­Ë¦³µÇ¬r­G¼ìºÅ
·|­û:dk10140377µoªí®É¶¡:2022/10/2 ¤W¤È 10:57:12²Ä2576½g¦^À³
´º³Í³£±ÂÅv¤F¡AªYÄ£¬O­nµ¥¦h¤[

´º³Í³o¨Ç·s»D¤§«eª£¹L¤F ³o¤]¯à¼Q40% ¤ºÀ`¤Ó²r¤F

¤£­n³Q¶W¨®¤F!!

========================

§Oºô³£¦bª`·N·sÃĤF ¤£ª¾¬O¦n¬OÃa

¬Ý¬Ý¨º¨Ç¤£·Çªº¦Ñ¿é

§Ú­n¦^À³¥»¸ÜÃD
·|­û:
§@ªÌ:
¬ÛÃöªÑ²¼¤½¥q¦WºÙ:ªYÄ£¥ÍÂå
¤º®e:
½Ð¥ýµn¤J­Y±z©|µL·|­û¨­¤À¡A½Ð¥ý¥Ó½Ð±b¸¹
°Q½×°Ï¬ÛÃö³W©w¡G
1.­Y±b¸¹¶¢¸m¹L¤[¨t²Î·|¦Û°Êµn¥X¡A«Øij¦b¼g¦n¤å³¹¨Ã¥B©|¥¼µo°e¤§«e¥ý¦æ½Æ»s¡A¥H§Kµo°e¥¢±Ñ«á¾É­P¤º¤å®ø¥¢¡I
2.½Ð¤Å°Q½×ªÑ²¼¶R½æ©Î´£¤Î¦¨¥æ»ù¦ìµ¥¨Æ©y¡A¤Z¬O¯d¤U¬ÛÃö¥æ©ö°T®§¡A¥»ºô±N¦Û°Ê§R°£¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
3.ÄY¸T¯d¤UÁpµ¸¤è¦¡¡A½Ñ¦pLINE¡BFB¡BE-mail¡B¹q¸Ü..µ¥¡A©Î¥H¥ô¦ó©ú¥Ü¡B·t¥Üµ¥¤âªk¶i¦æÁpµ¸¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
4.¬°ÁקK®ö¶Oºô¸ô¸ê·½¡A½Ð¤Å±N¬Û¦P¤º®e³sÄòµo¦b¦h­Ó¤£¦P¥DÃD¤º¡A©ÎªÌ³sÄòµo°e¦h­Ó·s¥DÃD¡A­Y¦³¦¹Ãþ¬~ª©¤§¦æ¬°±NµLªkÄ~Äò°Ñ»P°Q½×¡I
5.ÄY¸T·N¹ÏÂǥΥ»ºô¥­¥x¤½µM´²¥¬¤å¦r©ó²³¡A¦Ó«üÂÖ¡B«V°d©Î¶Ç­z¨¬¥H·´·l¥L¤H¦WÅA¤§¨ÆªÌ¡A­Y¦]¦Ó¯A¤Îªk«ß°ÝÃD¡A·§»P¥»¤½¥qµLÃö¡A·q½Ð¿í¦u¡C

·q½Ð´L­«¥»ºô¤§¸gÀç²z©À¨Ã¿í¦uª©³W¡AÁÂÁ¡C

¼s§i¦X§@ ¥¼¤W¥«ÂdªÑ²¼¬d¸ß ¥¼¤W¥«ºô¯¸¾ÉÄý ¥¼¤W¥«ÂdªÑ²¼±MÃD ¿³ÂdªÑ²¼±MÃD ¥¼¤W¥«ªÑ²¼-¶°¹Î¤ÀÃþ ²§·~Âà§ë¸ê¥Í§Þ·~ ¤U³æ±Ð¾Ç
¥¼¤W¥«|¥¼¤W¥«ªÑ²¼|³Ì±M·~ªº  ¥xÆW¥¼¤W¥«ªÑ²¼  °]¸gºô¯¸-Copyright©2022¡£¥²´Iºô¡¤ §K¥I¶OªA°È±M½u:0800-035-178 ªA°È«H½c:postmaster@berich.com.tw
¥»ºô¯¸¬° ¥¼¤W¥«ÂdªÑ²¼¬d¸ß,¥¼¤W¥«ªÑ²¼§Y®É·s»D,¥¼¤W¥«¤½¥q¤½§i,¿³ÂdªÑ²¼¶R½æ,·Ç¤W¥«ªÑ²¼,¤¤ÅҪѬÛÃö¸ê°T¤À¨É¥æ¬yªÀ¸sºô¯¸,¸ê®Æ¶È¨Ñ°Ñ¦Ò,¨Ï¥ÎªÌ½Ð¦Û¦æ·r°u!
¥»ºô¯¸¤£¤¶¤J·|­û¶¡¤§¥¼¤W¥«ªÑ²¼¶R½æ,³æ¯Â´£¨Ñ¥¼¤W¥«ªÑ²¼¦æ±¡,«ùªÑÂàÅý,¥¼¤W¥«ªÑ²¼¹L¤á¿Ô¸ß¶È´£¨Ñ¥¼¤W¥«ªÑ²¼¥æ©ö¥­¥xµ¹·|­û¨Ï¥Î,¨Ì¥»¸ê®Æ¥æ©ö«á¬ÕÁ«¦Û­t!